XOMA (XOMA Royalty) Tariff Resilience Score: 7/10 (As of Jul. 13, 2026)


XOMA XOMA Royalty Corp XOMA
45 GF Score
Price $41.54
GF Value $18.91
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty Tariff Resilience Score?

XOMA Royalty XOMA -6.06% 45 Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus rates XOMA with a GF Score™ of 45/100 and a GF Value™ of $18.91 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,370 Biotechnology companies, XOMA Royalty ranks better than 90.36% on this metric.

XOMA Royalty has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

XOMA Royalty has XOMA's business model focuses on royalties, limiting direct exposure to tariffs. However, its partners' supply chains could indirectly affect revenue.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes XOMA Royalty might have Highly Resilient.

XOMA Royalty  (NAS:XOMA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

XOMA Royalty Tariff Resilience Score Related Terms

XOMA vs CLYM, CTMX, ALLO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, XOMA Royalty's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA Royalty Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Tariff Resilience Score falls into.


XOMA
45GF Score
XOMA Royalty Corp XOMA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
XOMA Royalty (XOMA) has a Tariff Resilience Score of 7 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, XOMA Royalty ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is XOMA Royalty's Tariff Resilience Score too high?
XOMA Royalty's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. XOMA Royalty's value of 7 is 75% above this industry median. Based on the distribution chart, XOMA Royalty ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's Tariff Resilience Score compare to CLYM and CTMX?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #132 out of 1370 companies for Tariff Resilience Score. This places XOMA Royalty in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. XOMA Royalty's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XOMA Royalty's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XOMA Royalty's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.91, compared to a current price of $41.54 — trading 119.7% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XOMA Royalty (XOMA) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $41.54 is trading 119.7% above its estimated GF Value™ of $18.91. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for XOMA:

  • Tariff Resilience Score: 7
  • GF Value™: $18.91 vs. price of $41.54 (119.7% above fair value)
  • GF Score™: 45/100 with 9 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1370)

No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score

Get the complete analysis for XOMA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.54
Price
$18.91
GF Value